Straits Times Index
3,011.55-3.23(-0.11%)Nikkei
28,864.32-65.79(-0.23%)Hang Seng
29,098.29-138.50(-0.47%)
Mountain Valley MD Holdings Inc. (MVMDF)
| Previous close | 1.0600 |
| Open | 1.0300 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.8730 - 1.0599 |
| 52-week range | 0.0421 - 2.0000 |
| Volume | 752,223 |
| Avg. volume | 384,416 |
| Market cap | 243.393M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- CNW Group
Mountain Valley MD Proceeding with FDA 505(b)(2) Pathway Application for Novel Ivectosol™
And provides update on its BSL-4 and Dose Sparing Adjuvant TrialsTORONTO, March 3, 2021 /CNW/ - Mountain Valley MD Holdings Inc. (the "Company" or "MVMD") (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it has contracted Camargo Pharmaceutical Services, LLC ("Camargo") to provide regulatory consulting services to support MVMD's pursuit of U.
- CNW Group
/R E P E A T -- Invitation to media - Élisabeth Brière to announce investment to support clean technology development in Cantons-de-l'Est/
EAST ANGUS, QC, March 2, 2021 /CNW Telbec/ - Canada Economic Development for Quebec Regions (CED)The Government of Canada considers the environment and clean technologies as key elements of the economic recovery.With this in mind, Élisabeth Brière, Parliamentary Secretary to the Minister of Economic Development and Official Languages (Economic Development Agency of Canada for the Regions of Quebec), the Honourable Mélanie Joly, invites media representatives to a press conference regarding assistance from Canada Economic Development for Quebec Regions for Concertaction Estrie (ADDERE).
- CNW Group
Mountain Valley MD Commencing Husbandry Animal Trials, Appoints Seasoned Doctor of Veterinary Medicine to Advisory Board
TORONTO, March 1, 2021 /CNW/ - Mountain Valley MD Holdings Inc. (the "Company" or "MVMD") (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it is commencing husbandry animal trials with a third-party preclinical contract research organization ("CRO") to validate the superiority of the Company's injectable solubilized Ivermectin technology, Ivectosol™ 1%, versus current commercially available forms to treat a broad category of animal parasites.
